Southside Place, TX Ketamine Therapy Clinic: Precision Treatment for Depression, Anxiety, PTSD, and Chronic Pain That Haven't Responded to Conventional Medicine

Living in one of Houston’s most informed, medically connected communities doesn’t immunize you from treatment-resistant depression. It may, in fact, sharpen the frustration. You’ve consulted top-tier psychiatrists. You’ve had access to the Medical Center’s resources. You’ve tried the medications they recommended — methodically, patiently, with full compliance — and the results haven’t matched the expertise behind the prescriptions. That disconnect isn’t about provider quality or patient effort. It’s about a ceiling built into the medications themselves.

Every conventional antidepressant — from the first SSRI your doctor prescribed to the augmentation strategy your psychiatrist added later — works within the same neurochemical framework: serotonin, norepinephrine, dopamine. These are legitimate pharmacological targets, and they help the majority of patients. But for the estimated one-third who don’t respond, the limitation isn’t in the prescriber’s skill. It’s in the mechanism. Chronic depression, anxiety, PTSD, and pain physically degrade the synaptic connections between neurons in brain regions responsible for mood regulation, emotional processing, and pain modulation. No drug targeting chemical messenger levels can reconstruct those connections. Ketamine can. It works through the glutamate pathway — the brain’s most extensive neural communication network — and triggers the rapid rebuilding of the synapses that chronic illness has eroded. Baylor College of Medicine, right here in the Texas Medical Center, led one of the largest studies to date comparing ketamine to electroconvulsive therapy, finding that ketamine demonstrated a 55% response rate versus 41% for ECT after three weeks — and with fewer cognitive side effects. Catalyst Health & Wellness delivers this treatment through three Houston-area clinics, each under the direct supervision of Dr. Ho — a board-certified anesthesiologist and former pediatrician whose dual expertise provides the precision dosing, real-time monitoring, and compassionate care that ketamine therapy demands.

Ketamine didn’t arrive in psychiatry as an experimental compound. It arrived with six decades of clinical credibility already established. Synthesized in 1962, FDA-approved as a general anesthetic in 1970, and continuously used across operating rooms, emergency departments, pediatric medicine, and military field hospitals since — ketamine’s safety profile is among the most comprehensively documented of any medication in active clinical use.

The psychiatric application emerged from an unexpected finding. In the late 1990s, researchers studying the glutamate system — the signaling network responsible for the overwhelming majority of excitatory neurotransmission in the brain — discovered that sub-anesthetic ketamine doses produced rapid, robust depression relief in patients who had failed every other treatment. Not modest improvement over weeks. Meaningful change within hours.

The mechanism is now well understood. Standard antidepressants boost serotonin, norepinephrine, or dopamine availability and wait for the brain’s slow neuroplastic response — four to eight weeks, when it occurs at all. Ketamine takes a fundamentally different approach. It blocks NMDA receptors in the glutamate system, triggering a biochemical cascade that releases brain-derived neurotrophic factor (BDNF) — the growth protein that physically constructs new synaptic connections in brain regions governing mood, threat processing, and pain regulation. Chronic conditions structurally thin these connections over time. Ketamine rebuilds them, often within a single treatment session. This shared biological deficit is why ketamine simultaneously improves depression, anxiety, PTSD, OCD, chronic pain, and suicidal thinking — conditions that appear clinically distinct but stem from the same underlying neural erosion.